American Heart Journal
Volume 156, Issue 2 , Pages 315-321 , August 2008

Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: Evidence of improved vascular α1-adrenoreceptor signal transduction

  • Benjamin W. Van Tassell, PharmD, BCPS

      Affiliations

    • Department of Pharmacotherapy, University of Utah, Salt Lake City, UT
    • Corresponding Author InformationReprint requests: Benjamin W. Van Tassell, PharmD, BCPS, University of Utah, 30 South, 2000 East, Rm #258, Salt Lake City, UT 84112.
    • ,
  • Matthew T. Rondina, MD

      Affiliations

    • Department of Medicine, University of Utah, Salt Lake City, UT
    • ,
  • Franklin Huggins, PharmD

      Affiliations

    • Department of Pharmacotherapy, University of Utah, Salt Lake City, UT
    • ,
  • Edward M. Gilbert, MD

      Affiliations

    • Department of Medicine, University of Utah, Salt Lake City, UT
    • ,
  • Mark A. Munger, PharmD, FCCP

      Affiliations

    • Department of Pharmacotherapy, University of Utah, Salt Lake City, UT
    • Department of Medicine, University of Utah, Salt Lake City, UT

Received 12 February 2008 ,Accepted 1 April 2008.

References 

  1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13
  2. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  3. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13
  4. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17(Suppl B):8–16
  5. Ruffolo RR, Gellai M, Hieble JP, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38(Suppl 2):82–88
  6. Woodcock EA. Roles of alpha1A- and alpha1B-adrenoceptors in heart: insights from studies of genetically modified mice. Clin Exp Pharmacol Physiol. 2007;34:884–888
  7. Packer M, Medina N, Yushak M. Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. J Am Coll Cardiol. 1986;7:671–680
  8. Sumner DJ, Elliott HL, Reid JL. Analysis of the pressor dose response. Clin Pharmacol Ther. 1982;32:450–458
  9. Semplicini A, Pessina AC, Rossi GP, et al. Alpha-adrenoceptor blockade by labetalol during long-term dosing. Clin Pharmacol Ther. 1983;33:278–282
  10. Tham TC, Guy S, McDermott BJ, et al. The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man. Br J Clin Pharmacol. 1995;40:19–23
  11. Dunnett C, Goldsmith C. When and how to do multiple comparisons. In:  Buncher C,  Tsay J editor. Statistics in the pharmaceutical industry. 3rd ed.. New York: Chapman & Hall; 2006;p. 421–452
  12. Ting N. Dose finding in drug development. Springer; 2006;
  13. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation. 2002;106:2194–2199
  14. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26:2259–2268
  15. Hansson L, Himmelmann A. Carvedilol in the treatment of hypertension—a review of the clinical data base. Scand Cardiovasc J Suppl. 1998;47:67–80
  16. Lund-Johansen P, Omvik P, Nordrehaug JE, et al. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S27–S34
  17. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499–1506
  18. Metra M, Nardi M, Giubbini R, et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678–1687
  19. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225–1231
  20. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817–2825
  21. Giannattasio C, Cattaneo BM, Seravalle G, et al. Alpha 1-blocking properties of carvedilol during acute and chronic administration. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S18–S22
  22. Kubo T, Azevedo ER, Newton GE, et al. Lack of evidence for peripheral alpha(1)-adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J Am Coll Cardiol. 2001;38:1463–1469
  23. Creager MA, Creager SJ. Arterial baroreflex regulation of blood pressure in patients with congestive heart failure. J Am Coll Cardiol. 1994;23:401–405
  24. Goldsmith SR, Francis GS, Cohn JN. Norepinephrine infusions in congestive heart failure. Am J Cardiol. 1985;56:802–804
  25. Graham RM, Thornell IR, Gain JM, et al. Prazosin: the first-dose phenomenon. Br Med J. 1976;2:1293–1294
  26. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289:712–718
  27. Movsesian MA, Bristow MR. Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. Curr Top Dev Biol. 2005;68:25–48
  28. Vatner DE, Asai K, Iwase M, et al. Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart. Am J Cardiol. 1999;83:80H–85H
  29. Sigmund M, Jakob H, Becker H, et al. Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Eur J Clin Pharmacol. 1996;51:127–132
  30. Gilbert EM, Olsen SL, Renlund DG, et al. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;71:23C–29C
  31. Kubo H, Margulies KB, Piacentino V, et al. Patients with end-stage congestive heart failure treated with beta-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation. 2001;104:1012–1018
  32. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002;346:1357–1365
  33. Heilbrunn SM, Shah P, Bristow MR, et al. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483–490
  34. Bradley JG, Davis KA. Orthostatic hypotension. Am Fam Physician. 2003;68:2393–2398
  35. Lipsitz LA. Orthostatic hypotension in the elderly. N Engl J Med. 1989;321:952–957
  36. Ooi WL, Barrett S, Hossain M, et al. Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population. JAMA. 1997;277:1299–1304
  37. Koshimizu TA, Tsujimoto G, Hirasawa A, et al. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004;63:662–672
  38. Yang M, Ruan J, Voller M, et al. Differential regulation of human alpha1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:439–446
  39. Lei B, Zhang Y, Han C. Sustained norepinephrine stimulation induces different regulation of expression in three alpha1-adrenoceptor subtypes. Life Sci. 2001;69:301–308

 Funding: GlaxoSmithKline Investigator Initiated Trials.

 Conflict of interest: Benjamin W. Van Tassell, none; Matthew Rondina, none; Franklin Huggins, none; Mark A. Munger, GlaxoSmithKline Speakers Bureau and Research Grant Support; Edward M. Gilbert, GlaxoSmithKline Speakers Bureau and Research Grant Support.

PII: S0002-8703(08)00279-2

doi: 10.1016/j.ahj.2008.04.004

American Heart Journal
Volume 156, Issue 2 , Pages 315-321 , August 2008

Article Tools

* Image Usage & Resolution